Metastatic Prostate Cancer

A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.

The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.

In this video, Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic, discusses the effective of androgen deprivation therapy on metastatic hormone-sensitive prostate cancer.

The FDA granted priority review to darolutamide in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer.

Social media has become the primary communication mode of the 21st century, and many physicians have started incorporating it into their practices.

Increases in metastatic prostate cancer incidence may be temporally associated with changes in clinical policy following U.S. Preventive Services Task Force recommendations, according to a study in JAMA Network Open.

SAN FRANCISCO — Bavdegalutamide demonstrated clinical activity among heavily pretreated men with metastatic castration-resistant prostate cancer who received novel hormonal agents, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Continued enzalutamide, after progression on the drug, in combination with docetaxel significantly extended PFS compared with placebo and docetaxel among men with metastatic castration-resistant prostate cancer, study results showed.

SAN FRANCISCO — The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.